CBAY Seeing the 135% move in CBAY shows me that the market wants treatment options for liver disease. At these prices THTX is an acquisition target should the right pharma be interested and motivated. It's never a good reason to buy a stock (for a buyout) but in this case, it's just one more reason. Again, I am biased and do believe we will see material upside because there are very few sellers left. If you didn't sell on the way to 1.93, you're very likely to hold for the long term.